The Impact of Host Metabolic Factors on Treatment Outcome in Chronic Hepatitis C

Table 2

Variable associations with SVR.

	SVR; (𝑛=251)	Response failure; (𝑛=105)	𝑃 values
Gender (males%)	145 (57.8)	52 (49.5)	0.154
Age ≥ 40 years (𝑛%)	123 (49.60)	80 (77.7)	<0.001
IVDU (𝑛%)	95 (37.8)	16 (15.4)	<0.001
Alcohol abuse (𝑛%)	27 (11.2)	14 (14.1)	0.442
BMI (kg/m^2)	23.1±3.8	24.6±4.5	0.035
Overweight (𝑛%)	24 (28.6)	25 (50.0)	0.013
Genotype distribution			<0.001
Genotype 1	111 (45.5)	53 (52.5)
Genotype 2	17 (7.0)	6 (5.9)
Genotype 3	98 (40.2)	15 (14.9)
Genotype 4	18 (7.4)	27 (26.7)
High viral load (𝑛%)	39 (40.6)	28 (45.8)	0.515
Abnormal ALT (𝑛%)	236 (96.7)	95 (95.0)	0.447
Abnormal AST (𝑛%)	199 (86.1)	77 (86.5)	0.931
Hepatic steatosis (𝑛%)	64 (25.7)	49 (46.7)	<0.001
Severe inflammation (𝑛%)	9 (3.8)	8 (8.5)	0.080
Advanced fibrosis (𝑛%)	26 (10,5)	30 (28,6)	<0.001
Cirrhosis (𝑛%)	7 (2,8)	14 (13,3)	<0.001
Type of IFN			0.987
PegIFNα-2a (𝑛%)	69 (28.6)	27 (28.7)
PegIFNα-2b (𝑛%)	172 (71.4)	67 (71.3)
Dosage adherence (𝑛%)	173 (80.8)	60 (82.2)	0.799